Viewing Study NCT02587650

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 5:07 PM

Ignite Modification Date: 2026-02-18 @ 11:51 PM

Study NCT ID: NCT02587650

Status: TERMINATED

Last Update Posted: 2020-01-27

First Post: 2015-10-23

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Sponsor: University of California, San Francisco

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Adverse Events Module Baseline Characteristics Module Participant Flow Module